247 related articles for article (PubMed ID: 28715437)
21. Prognostic significance of TAZ expression in resected non-small cell lung cancer.
Xie M; Zhang L; He CS; Hou JH; Lin SX; Hu ZH; Xu F; Zhao HY
J Thorac Oncol; 2012 May; 7(5):799-807. PubMed ID: 22481233
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of serum soluble interleukin-23 receptor and related T-helper 17 cell cytokines in non-small cell lung carcinoma.
Liu D; Xing S; Wang W; Huang X; Lin H; Chen Y; Lan K; Chen L; Luo F; Qin S; Liang R; Bai C; Xu J; Liu W
Cancer Sci; 2020 Apr; 111(4):1093-1102. PubMed ID: 32020720
[TBL] [Abstract][Full Text] [Related]
23. Serum concentrations of proinflammatory cytokines in advanced non small cell lung cancer patients.
De Vita F; Orditura M; Auriemma A; Infusino S; Catalano G
J Exp Clin Cancer Res; 1998 Dec; 17(4):413-7. PubMed ID: 10089060
[TBL] [Abstract][Full Text] [Related]
24. Predictive and prognostic effect of CD133 and cancer-testis antigens in stage Ib-IIIA non-small cell lung cancer.
Su C; Xu Y; Li X; Ren S; Zhao C; Hou L; Ye Z; Zhou C
Int J Clin Exp Pathol; 2015; 8(5):5509-18. PubMed ID: 26191258
[TBL] [Abstract][Full Text] [Related]
25. Overexpression of Pokemon in non-small cell lung cancer and foreshowing tumor biological behavior as well as clinical results.
Zhao ZH; Wang SF; Yu L; Wang J; Chang H; Yan WL; Zhang J; Fu K
Lung Cancer; 2008 Oct; 62(1):113-9. PubMed ID: 18550205
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of interferon-gamma, interleukin-6, and tumor necrosis factor-alpha in the radiation response of patients diagnosed with locally advanced non-small-cell lung cancer and glioblastoma multiforme.
Deniz ÇD; Gürbilek M; Koç M
Turk J Med Sci; 2018 Feb; 48(1):117-123. PubMed ID: 29479968
[TBL] [Abstract][Full Text] [Related]
27. A promising role of interferon regulatory factor 5 as an early warning biomarker for the development of human non-small cell lung cancer.
Guo J; Wang X; Wang Y; Wang L; Hua S
Lung Cancer; 2019 Sep; 135():47-55. PubMed ID: 31447002
[TBL] [Abstract][Full Text] [Related]
28. Identification of serum inflammatory markers as classifiers of lung cancer mortality for stage I adenocarcinoma.
Meaney CL; Zingone A; Brown D; Yu Y; Cao L; Ryan BM
Oncotarget; 2017 Jun; 8(25):40946-40957. PubMed ID: 28402963
[TBL] [Abstract][Full Text] [Related]
29. Expression of flotillin-2 in human non-small cell lung cancer and its correlation with tumor progression and patient survival.
Wang YL; Yao WJ; Guo L; Xi HF; Li SY; Wang ZM
Int J Clin Exp Pathol; 2015; 8(1):601-7. PubMed ID: 25755751
[TBL] [Abstract][Full Text] [Related]
30. An immunohistochemical study of cyclin-dependent kinase 5 (CDK5) expression in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC): a possible prognostic biomarker.
Wei K; Ye Z; Li Z; Dang Y; Chen X; Huang N; Bao C; Gan T; Yang L; Chen G
World J Surg Oncol; 2016 Feb; 14(1):34. PubMed ID: 26860827
[TBL] [Abstract][Full Text] [Related]
31. Interstitial tumor-associated macrophages combined with tumor-derived colony-stimulating factor-1 and interleukin-6, a novel prognostic biomarker in non-small cell lung cancer.
Pei BX; Sun BS; Zhang ZF; Wang AL; Ren P
J Thorac Cardiovasc Surg; 2014 Oct; 148(4):1208-1216.e2. PubMed ID: 24907005
[TBL] [Abstract][Full Text] [Related]
32. CXCR4 overexpression is associated with poor outcome in females diagnosed with stage IV non-small cell lung cancer.
Otsuka S; Klimowicz AC; Kopciuk K; Petrillo SK; Konno M; Hao D; Muzik H; Stolte E; Boland W; Morris D; Magliocco AM; Bebb DG
J Thorac Oncol; 2011 Jul; 6(7):1169-78. PubMed ID: 21623238
[TBL] [Abstract][Full Text] [Related]
33. Elevated plasma interleukin-35 levels predict poor prognosis in patients with non-small cell lung cancer.
Gu X; Tian T; Zhang B; Liu Y; Yuan C; Shao L; Guo Y; Fan K
Tumour Biol; 2015 Apr; 36(4):2651-6. PubMed ID: 25480413
[TBL] [Abstract][Full Text] [Related]
34. Analysis of pro- and anti-inflammatory cytokine gene variants and serum cytokine levels as prognostic markers in breast cancer.
Kaur RP; Vasudeva K; Singla H; Benipal RPS; Khetarpal P; Munshi A
J Cell Physiol; 2018 Dec; 233(12):9716-9723. PubMed ID: 30078181
[TBL] [Abstract][Full Text] [Related]
35. [Prognostic factors in patients with stage III and IV non-small cell lung cancer].
Song LH; Song XR; Liu MQ; Zhang XQ; Zheng L; Li XJ; Liu PX
Zhonghua Zhong Liu Za Zhi; 2004 Jun; 26(6):345-8. PubMed ID: 15312344
[TBL] [Abstract][Full Text] [Related]
36. Lack of interleukin-10 expression could predict poor outcome in patients with stage I non-small cell lung cancer.
Soria JC; Moon C; Kemp BL; Liu DD; Feng L; Tang X; Chang YS; Mao L; Khuri FR
Clin Cancer Res; 2003 May; 9(5):1785-91. PubMed ID: 12738735
[TBL] [Abstract][Full Text] [Related]
37. OTUD7B and NIK expression in non-small cell lung cancer: Association with clinicopathological features and prognostic implications.
Zhang B; Wang H; Yang L; Zhang Y; Wang P; Huang G; Zheng J; Ren H; Qin S
Pathol Res Pract; 2016 Oct; 212(10):893-898. PubMed ID: 27499151
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of angiopoietin-2 in non-small cell lung cancer patients: a meta-analysis.
Xuan ZX; Zhang S; Yuan SJ; Wang W; Yu J
World J Surg Oncol; 2016 Sep; 14(1):237. PubMed ID: 27589869
[TBL] [Abstract][Full Text] [Related]
39. The relationship between Glasgow Prognostic Score and serum tumor markers in patients with advanced non-small cell lung cancer.
Jiang AG; Chen HL; Lu HY
BMC Cancer; 2015 May; 15():386. PubMed ID: 25956656
[TBL] [Abstract][Full Text] [Related]
40. Reduced expression of cyclin D2 is associated with poor recurrence-free survival independent of cyclin D1 in stage III non-small cell lung cancer.
Ko E; Kim Y; Park SE; Cho EY; Han J; Shim YM; Park J; Kim DH
Lung Cancer; 2012 Aug; 77(2):401-6. PubMed ID: 22534667
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
